Truist raised the firm’s price target on Quest Diagnostics (DGX) to $192 from $190 and keeps a Hold rating on the shares. Quest’s Q2 results came in ahead of consensus expectations on the top- and bottom-lines, with FY25 guidance moved up as core demand trends remain strong, organic volumes were solid with brisk organic revenue and organic growth expectations were raised, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DGX:
- Quest Diagnostics price target raised to $178 from $160 at Deutsche Bank
- Quest Diagnostics: Strong Financial Outlook and Strategic Positioning Justify Buy Rating
- Quest Diagnostics: Strong Performance and Growth Potential Justify Buy Rating
- Quest Diagnostics Reports Strong Q2 2025 Results
- Quest Diagnostics Reports Strong Growth in Earnings Call